VDJ-029

N/A

Report date: 2025/06/09 17:26:48

Base Information

Drug NameVDJ-029
Drug Alias NameVDJ-029VDJ029
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-23 subunit p19 inhibitorsInterleukin-6 receptor subunit beta modulators
TargetsInterleukin-23 subunit p19Interleukin-6 receptor subunit beta
Therapy Area/IndicationsAtherosclerosisRenal Insufficiency, ChronicGraves Ophthalmopathy +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Vdjbio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Vdjbio Co Ltd
Inactive CompaniesN/A
Active IndicationsAtherosclerosisRenal Insufficiency, ChronicGraves Ophthalmopathy +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A